| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, CEO, Chairman | EVP and Chief Strategy Officer
1 company
Lance Alstodt last filed a Form 4 in October 2025, as President, CEO, Chairman at BRTX. From August 2019 to October 2025, the filings on record show 33 open-market purchases and 0 sales. Lance Alstodt's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Lance Alstodt's trades have earned a middling insider score of 55/100 across 29 rated trades. Over a 12-month horizon, 37.9% of those trades were profitable, with an average 12-month return of -10.2%.
At the last filing, the largest reported position was 187,497 shares of BRTX. Net of sales, the BRTX filings show accumulation of 83,552 shares.
Shares as reported in the last Form 4 for each company; the most recent is from October 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 5, 2019 | BRTX Biorestorative Therapies, Inc. | EVP and Chief Strategy Officer | Buy | 10,000 | $0.27 | $2,697.50 | +50.0% | |
| Aug 27, 2019 | BRTX Biorestorative Therapies, Inc. | EVP and Chief Strategy Officer | Buy | 10,000 | $0.28 | $2,761.00 | +100.0% | |
| Aug 21, 2019 | BRTX Biorestorative Therapies, Inc. | EVP and Chief Strategy Officer | Buy | 10,000 | $0.25 | $2,498.00 | New |